Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 216,600 shares on February 27, indicating growing investor interest in the company [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have increased their holdings for 5 days, with a total net increase of 4.476 million shares [1] - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.401 million shares [1] - Currently, southbound funds hold 75.921 million shares of Baize Medical, representing 5.75% of the company's issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 357,000 shares on February 26, indicating a growing interest in the company within the investment community [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have increased their holdings on 4 days, with a total net increase of 2.7846 million shares [1] - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.2084 million shares [1] - Currently, southbound funds hold 75.7044 million shares of Baize Medical, representing 5.73% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 1.9632 million shares on February 23, indicating growing investor interest in the company [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have increased their holdings on 3 days, with a total net increase of 870,000 shares [1] - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.2756 million shares [1] - Currently, southbound funds hold 75.3474 million shares of Baize Medical, representing 5.71% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company conducts cancer diagnosis, treatment, rehabilitation, and end-of-life care for patients, as well as early cancer screening, tumor vaccination, and health management services for other potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has taken a significant step in its international strategy by signing a memorandum of cooperation with National Hospital in Indonesia to establish a comprehensive oncology service center, marking a milestone in the company's globalization efforts and enhancing China's high-end medical technology's international influence [1] Group 1: Strategic Collaboration - The partnership aims to create a high-level oncology diagnosis and treatment service platform in Indonesia, addressing the common issue of cancer medical resource shortages in Southeast Asia and providing a replicable "Indonesian model" [1] - Meizhong Jiahe has developed a comprehensive solution that includes advanced technologies such as proton therapy and precision radiotherapy, along with a full-chain empowerment system covering personalized plan design, equipment optimization, clinical quality control, and standardized treatment processes [2] Group 2: Technological Innovation - The introduction of Meizhong Jiahe's self-developed tumor treatment model and AI-assisted diagnosis system signifies a new phase of intelligent empowerment in the collaboration, enhancing local doctors' diagnostic efficiency and accuracy [2] - The digital platform will facilitate cross-border medical collaboration, enabling real-time cooperation between Meizhong Jiahe's expert team and Indonesian doctors for complex case management [2] Group 3: Sustainable Development - The core of the collaboration is not merely technology transfer but building a comprehensive oncology medical service ecosystem in Indonesia and Southeast Asia, utilizing a "sister hospital" model for deep medical personnel exchanges and training [3] - The globalization strategy will unfold in three phases: solidifying regional footholds, building a core ecosystem of medical technology empowerment and AI-driven services, and achieving value co-creation for long-term growth [3] Group 4: Vision for the Future - The company aims to expand into the Southeast Asian market, focusing on delivering patient-centered care and creating a comprehensive oncology medical ecosystem that encompasses diagnosis, treatment, rehabilitation, and research [4]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 1.6494 million shares on February 13, with a total net increase of 467,400 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 8.016 million shares [1] - As of now, southbound funds hold 73.0944 million shares of Baize Medical, representing 5.54% of the company's total issued ordinary shares [1] Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - Services provided include cancer diagnosis, treatment, rehabilitation, end-of-life care, early cancer screening, cancer vaccination, and health management services for potential healthy populations [1] - The company primarily operates in the Chinese market [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.4748 million shares on February 12, with a total net reduction of 1.5456 million shares over the past five trading days [1] - Over the last 20 trading days, there have been 10 days of net increases in southbound fund holdings, totaling 5.3742 million shares [1] - As of now, southbound funds hold 71.445 million shares of Baize Medical, representing 5.41% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Core Insights - Southbound funds reduced their holdings in Baize Medical (02609.HK) by 1.5576 million shares on February 11, indicating a trend of net selling over the past five trading days, with a total net reduction of 775,800 shares [1] - Over the last 20 trading days, there were 11 days of net buying by southbound funds, accumulating to a total net increase of 6.9 million shares [1] - As of now, southbound funds hold 72.9198 million shares of Baize Medical, representing 5.52% of the company's total issued ordinary shares [1] Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also provides cancer diagnosis, treatment, rehabilitation, and end-of-life care, along with early cancer screening, cancer vaccination, and health management services for other potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 327,000 shares on February 10, with a total net reduction of 64,200 shares over the past five trading days [1] - Over the last 20 trading days, there were 11 days of net increases in southbound fund holdings, totaling 7,309,800 shares [1] - As of now, southbound funds hold 74,477,400 shares of Baize Medical, representing 5.64% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 2.17 million shares on February 9, 2026, indicating growing investor interest in the company [1]. Group 1: Shareholding Changes - In the last 5 trading days, Baize Medical has seen a net increase of 3.31 million shares from southbound funds over 2 days [1]. - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.16 million shares [1]. - As of February 9, 2026, southbound funds hold 74.80 million shares of Baize Medical, representing 5.66% of the company's total issued ordinary shares [1]. Group 2: Trading Data - On February 9, 2026, the total shareholding was 74.80 million, with a change of 2.17 million shares, reflecting a 3.00% increase [2]. - On February 6, 2026, the total shareholding was 72.63 million, with a decrease of 0.36 million shares, showing a -0.50% change [2]. - On February 5, 2026, the total shareholding was 72.99 million, with a decrease of 0.70 million shares, indicating a -0.96% change [2]. - On February 4, 2026, the total shareholding was 73.70 million, with a decrease of 0.84 million shares, reflecting a -1.13% change [2]. - On February 3, 2026, the total shareholding was 74.54 million, with an increase of 3.04 million shares, showing a 4.26% change [2]. Group 3: Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [2]. - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [2]. - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2].

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a reduction of 705,000 shares on February 5, while showing a net increase of 1,264,800 shares over the past five trading days [1] - Over the last 20 trading days, Baize Medical experienced net purchases from southbound funds on 12 occasions, totaling 7,593,600 shares [1] - As of now, southbound funds hold 72,990,600 shares of Baize Medical, representing 5.53% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]